TISIDB

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00104 Ligand-binding domain of nuclear hormone receptor PF11825 Nuclear/hormone receptor activator site AF-1 PF00105 Zinc finger
Function	Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006352 DNA-templated transcription, initiation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0009755 hormone-mediated signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0043401 steroid hormone mediated signaling pathway GO:0048384 retinoic acid receptor signaling pathway GO:0048545 response to steroid hormone GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:1901522 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus
Molecular Function	GO:0003707 steroid hormone receptor activity GO:0003708 retinoic acid receptor activity GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004886 9-cis retinoic acid receptor activity GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03320 PPAR signaling pathway hsa04919 Thyroid hormone signaling pathway hsa04920 Adipocytokine signaling pathway
Reactome	R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-383280: Nuclear Receptor transcription pathway R-HSA-162582: Signal Transduction R-HSA-5362517: Signaling by Retinoic Acid

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RXRG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RXRG in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RXRG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.276	0.75
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.833	0.667
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.137	0.927
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.163	0.0898
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.647	0.59
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.813	0.195
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.566	0.588
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.868	0.601
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.012	0.994
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.506	0.504
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.338	0.18
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.513	0.0379

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RXRG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RXRG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RXRG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RXRG. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RXRG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RXRG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RXRG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RXRG
Name	retinoid X receptor, gamma
Aliases	NR2B3; nuclear receptor subfamily 2 group B member 3; RXRC; Retinoid X receptor gamma; Retinoic acid recepto ......
Chromosomal Location	1q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RXRG collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting RXRG.

ID	Name	Drug Type	Targets	#Targets
DB00210	Adapalene	Small Molecule	RARA, RARB, RARG, RXRA, RXRB, RXRG	6
DB00307	Bexarotene	Small Molecule	RXRA, RXRB, RXRG	3
DB00412	Rosiglitazone	Small Molecule	ACSL4, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG	7
DB00459	Acitretin	Small Molecule	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG	7
DB00523	Alitretinoin	Small Molecule	CYP26C1, IGFBP3, PSG5, RARA, RARB, RARG, RXRA, RXRB, RXRG	9
DB00755	Tretinoin	Small Molecule	ALDH1A1, ALDH1A2, CYP26A1, CYP26B1, CYP26C1, GPRC5A, HPGDS, LCN1, ......	19
DB00926	Etretinate	Small Molecule	RARA, RARB, RARG, RXRA, RXRB, RXRG	6
DB01393	Bezafibrate	Small Molecule	NR1I2, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG	7
DB02746	Phthalic Acid	Small Molecule	ESR1, ESR2, PGR, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG	9
DB03756	Doconexent	Small Molecule	PPARA, PPARG, RXRA, RXRB, RXRG, SREBF1	6

Browse RXRG